PHILADELPHIA – A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates ...

Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it. After treatment with CAR-T ...

Gilead was prepared to pay close to $12 billion to gain access to the CAR-T treatment, which was approved and emerged on the market just six weeks after Novartis’ rival therapy launched.

CAR-T cell therapy, a breakthrough immunotherapy that reprograms a patient’s own immune cells to attack cancer, could trigger “brain fog” — a condition marked by forgetfulness, confusion ...

Despite these advancements, more than 50% of patients with lymphoma do not have long-term remission with anti-CD19 CAR T-cell therapy. These patients have limited treatment options and poor prognoses.

The use of a regenerative medicine, specifically a CAR T-cell therapy, offers the potential to overcome barriers for other drug modalities to be effective in addressing DIPG, including the ...

Cognitive impairment after CAR-T cell therapy is typically mild; patients are not developing dementia, for instance. But it is frustrating and may not resolve on its own, Monje said.

A new Stanford Medicine-led study shows that CAR-T cell therapy causes mild cognitive impairments, independent of other cancer treatments, and that this happens via the same cellular mechanism as ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

BrainChild Bio advancing BCB-276 towards BLA submission with a single pivotal Phase 2 trial planned to commence in Q4 2025 The use of a regenerative medicine, specifically a CAR T-cell therapy ...